期刊文献+

2型糖尿病血清Afamin蛋白组学研究 被引量:2

Proteomics Research of Serum Afamin in Type 2 Diabetes
原文传递
导出
摘要 Afamin是与2型糖尿病(T2DM)密切相关的糖蛋白,本研究主要利用免疫印迹(Western Blot)和酶联免疫(ELISA)的方法研究T2DM血清Afamin的变化趋势,并进一步利用同位素标记相对和绝对定量(iTRAQ)方法以及免疫印迹的方法探讨并验证T2DM病人血清中Afamin糖基化修饰状态的变化。结果显示,T2DM病人Afamin条带灰度较健康对照显著增强(p=0.0101),血清Afamin在T2DM组和健康对照组浓度分别6.03±0.19μg/mL和5.07±2.12μg/mL,且两组之间具有显著性差异(p=0.0019);在Afamin高甘露糖型糖基化修饰异质性分析中,原血清以及Con A洗脱蛋白质中均检测到Afamin,而流穿蛋白质中未检测到Afamin,即所有血清Afamin都存在高甘露糖型糖链;iTRAQ标记定量数据显示血清高甘露糖型Afamin在T2DM中发生显著性上调,Western Blot结果验证了这一变化趋势(p=0.0462)。 Afamin is a sort of glycoprotein closely related to type 2 diabetes(T2DM).Western Blot and ELISA(enzyme linked immunosorbent assay)were used to analyze the changing trend of serum Afamin from T2DM,iTRAQ(isobaric tags for relative and absolute quantification)was applied to explore the glycosylation modified state of serum Afamin from T2DM,and Western Blot was adopted to validate this data.The results showed that Afamin appeared up-regulated significantly in T2DM(p=0.0101).The average content of serum Afamin was 6.03±0.19μg/mL in T2DM,which was 5.07±2.12μg/mL in the health control(p=0.0019).In high mannose heterogeneity analysis,we could see Afamin developing bands in crude serum and serum proteins eluted from Con A.However,we could not see Afamin band in the flow through.The results indicated that all of serum Afamin had high mannose glycan.The results of iTRAQ showed high mannose type Afamin was up-regulated in T2DM and Western Blot validated this data(p=0.0462).
作者 冯里茹 于微 刘小立 洪文旭 王俊 FENG Liru;YU Wei;LIU Xiaoli;HONG Wenxu;WANG Jun(Shenzhen Center for Chronic Disease Control,Shenzhen 518020,Guangdong,China)
出处 《武汉大学学报(理学版)》 CAS CSCD 北大核心 2021年第1期103-110,共8页 Journal of Wuhan University:Natural Science Edition
基金 国家自然科学基金(81673168,81202207) 广东省医学科学技术研究基金(A2020179) 深圳市卫生计生系统科研项目(SZXJ2017010) 深圳市科创委基础研究项目(JCYJ20170307144652484)。
关键词 2型糖尿病 糖基化 高甘露糖型 Afamin type 2 diabetes glycosylation high mannose type Afamin
  • 相关文献

参考文献4

二级参考文献86

  • 1Zhang Q B, Tang N, Brock J W C, et al. J. Proteome Res., 2007, 6 : 2323-2330.
  • 2Zhang H, Li X J, Martin D B, Aebersold R. Nature Bioteeh., 2003, 21 : 660-666.
  • 3Liu T, Qian W J, Gritsenko M A, et al. Mol. Cell. Proteomics, 2006, 5:1899-1913.
  • 4Liu T, Qian W J, Gritsenko M A, et al. J. Proteome Res., 2005,.4:2070--2080.
  • 5Lewandrowski U, Moebius J, Waiter U, Sickmann A. Mol. Cell. Proteomics, 2006, 5:226-233.
  • 6Rarnachandran P, Boontheung P, Xie Y M, et al. J. Proteome Res., 2006, 5:1493-1503.
  • 7Zhang H, Yi E C, H X J, et al. Mol. Cell. Proteomics, 2005, 4: 144-155.
  • 8Bernhard O K, Kapp E A, Simpson R J. J. Proteome Res., 2007, 6:987-995.
  • 9Zhou Y, Aehersold R, Zhang H. Anal. Chem., 2007, 79: 5826- 5837.
  • 10Tian Y, Zhou Y, Elliott S, et al. Nature Protocols, 2007, 2: 334- 339.

共引文献1335

同被引文献31

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部